NASDAQ:IRON Disc Medicine Q3 2026 Earnings Date & Estimates $62.06 +1.29 (+2.12%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$62.13 +0.07 (+0.11%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Disc Medicine is expected to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. The conference call is scheduled for October 30, 2026 at 9:30 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 5, 2026TimeBefore Market OpensConference Call DateOctober 30, 2026Conference Call9:30 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Disc Medicine in Q3 2026Disc Medicine is expected to post earnings of -$1.63 per share on revenue of $1.88 million. In the same quarter a year earlier Disc Medicine reported -$1.77 per share. Disc Medicine last reported on July 30, 2026, posting -$1.54 per share and beating the -$1.71 consensus estimate. Disc Medicine has beaten the consensus EPS estimate in 4 of its last 8 quarters.Consensus EstimatesConsensus EPS-$1.63Expected Revenue$1.88 millionPrior-Year EPS-$1.77Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$1.54 (Beat by +$0.17)EPS Beat Rate4 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Disc Medicine Q3 2026 Earnings FAQ When does Disc Medicine report Q3 2026 earnings? Disc Medicine (NASDAQ:IRON) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Disc Medicine's Q3 2026 earnings call? Disc Medicine's Q3 2026 earnings conference call is scheduled for Friday, October 30, 2026 at 9:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Disc Medicine? Analysts expect Disc Medicine to post earnings of -$1.63 per share for Q3 2026. How much revenue is Disc Medicine expected to report? The consensus revenue estimate for Disc Medicine is $1.88 million for Q3 2026. Disc Medicine Earnings HeadlinesDisc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your RightsOctober 5, 2026 | globenewswire.comRosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRONOctober 2, 2026 | prnewswire.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.October 11 at 1:00 AM | Profits Run (Ad)Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your RightsSeptember 28, 2026 | globenewswire.comROSEN, A LONGSTANDING LAW FIRM, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRONSeptember 27, 2026 | markets.businessinsider.comRosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRONSeptember 26, 2026 | prnewswire.comSee More Disc Medicine Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Disc Medicine? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Disc Medicine and other key companies, straight to your email. Email Address About Disc MedicineDisc Medicine (NASDAQ:IRON) is a clinical-stage biopharmaceutical company focused on developing treatments for serious hematologic diseases. The company’s research centers on disorders involving the production of red blood cells, iron metabolism and heme biology, areas that can contribute to anemia and other blood-related complications. Disc Medicine’s lead product candidate is bitopertin, an oral small-molecule therapy designed to modulate glycine transporter 1 and influence heme production. The company is evaluating bitopertin in conditions including erythropoietic protoporphyria, a rare disorder associated with painful light sensitivity, as well as polycythemia vera and other hematologic diseases. The company is also developing additional therapies intended to regulate iron availability and address anemia associated with chronic or hematologic conditions. Disc Medicine is headquartered in Cambridge, Massachusetts, and conducts clinical development activities primarily through research and clinical-trial networks. The company is led by President and Chief Executive Officer John Quisel and trades on the Nasdaq under the symbol IRON.View Disc Medicine ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes NextDelta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
